Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA Sitagliptin Add on to Metformin
NCT00833027Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoint: Change From Baseline in HbA1c at Week 24. Started Mar 2008; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00833027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833027.